Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

November 30th 2021

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

Dr. Stephens on Early Intervention With Targeted Agents in CLL

November 15th 2021

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

November 12th 2021

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Stephens Discusses Optimizing Treatment Selection in CLL

November 9th 2021

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Dr. Mato Discusses Advances in the Treatment of Patients With CLL

November 4th 2021

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Testing for Prognostic Markers Is a Necessity for Optimized CLL Care

November 3rd 2021

The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.

Dr. Danilov on the Rationale to Target MCL1 and BCLX in CLL

November 1st 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLL

October 27th 2021

Tadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.

Dr. Modi on the Utility of BTK Inhibitors in CLL

October 26th 2021

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Wierda on Future Research Directions With MRD in CLL

October 25th 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

October 25th 2021

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Abutalib on Recent Updates in CLL

October 25th 2021

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Dr. Wierda on Ongoing Research Efforts Examining Fixed-Duration Strategies in CLL

October 21st 2021

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

October 21st 2021

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Danilov on the Safety Profile of Entospletinib Plus Obinutuzumab in CLL

October 21st 2021

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

Experts Answer Audience Questions Related to Adverse Events of BTKi

October 21st 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, close out the program answering audience questions regarding potential adverse events surrounding the utilization of BTK inhibitors in the management of chronic lymphocytic leukemia.

Strategies for Managing Hypertension in Patients with CLL

October 21st 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review strategies for managing hypertension in patients with CLL.

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

October 21st 2021

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

October 21st 2021

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.